Gathering the record
Relay is organizing the evidence and source boundaries.
Recombinant human growth hormone
Somatropin is recombinant human growth hormone. Several FDA-approved brands treat defined pediatric growth disorders and adult growth hormone deficiency, but their indications, devices, concentrations, diluents, reconstitution, and storage instructions differ. It is not approved as a general anti-aging, bodybuilding, performance, or routine fat-loss drug.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Somatropin is laboratory-made human growth hormone. Several approved brands replace missing growth hormone in defined pediatric growth disorders and adult growth-hormone deficiency.
The approved record shows what hormone replacement can change when a true deficiency or defined growth disorder exists. Separate studies ask whether similar exposure benefits healthy aging, body composition, or physical function.
Controlled replacement trials support product-specific approved uses and can improve body composition or selected quality-of-life and bone measures in diagnosed adults. Healthy-aging studies found modest body-composition changes without reliable functional improvement and with more adverse effects.
The long-term benefit-risk balance outside diagnosed deficiency remains uncertain, especially for healthy aging, bodybuilding, performance, and routine fat loss. Brands, devices, concentrations, diluents, and handling instructions are not interchangeable.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A controlled replacement trial studied adults with confirmed growth-hormone deficiency caused by pituitary disease.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Multiple labels and decades of controlled research cover defined pediatric and adult deficiency indications.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Benefits and risks are well characterized in specific diagnosed populations, not bodybuilding or healthy aging.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The findings apply to diagnosed deficiency under monitored replacement. They do not establish benefit in healthy adults, athletes, anti-aging use, or interchangeability among approved and unapproved products. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple FDA-approved product programs and controlled replacement trials support somatropin for defined pediatric growth disorders and adult growth hormone deficiency; evidence and labeling are indication- and product-specific.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
The long-term benefit-risk balance when used outside diagnosed deficiency or approved pediatric indications, particularly for healthy aging, bodybuilding, performance, and exposure to unapproved or incorrectly handled products.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Unlike secretagogues, somatropin directly supplies growth hormone and activates the GH receptor systemically.
Genotropin, Humatrope, Norditropin, Omnitrope, and Zomacton do not all carry identical indication lists, devices, strengths, or preparation instructions.
Replacement is intended to restore a deficient hormone axis under clinical monitoring, not to push healthy physiology above normal ranges.
More lean mass on a scan did not consistently mean more strength, endurance, cognition, or independence.
Somatropin is a biologically active prescription hormone, not a low-risk wellness supplement.
Approved replacement and pediatric growth indications cannot be generalized to healthy adults seeking performance or cosmetic effects.
Some products are ready-to-use solutions, while others are lyophilized cartridges or vials with specific diluents and devices.
Mechanisms
Somatropin is a recombinant 191-amino-acid human growth hormone that directly activates the GH receptor and downstream JAK2-STAT and IGF-1 signaling. Licensed U.S. products include both ready-to-use solutions and lyophilized presentations with product-specific delivery systems. In diagnosed adult GH deficiency, randomized studies support changes in body composition, quality of life, and selected bone outcomes. In healthy older adults, trials and systematic review show modest lean-mass and fat-mass changes without consistent functional improvement and with increased edema, arthralgia, carpal-tunnel symptoms, gynecomastia, and glucose abnormalities. Approved deficiency and pediatric-growth evidence must not be generalized to anti-aging or athletic use.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Six-month double-blind randomized placebo-controlled period followed by open treatment
Adults with hypopituitarism and confirmed growth hormone deficiency
In adults with genuine GH deficiency, replacement increased fat-free mass, decreased fat mass, and improved selected quality-of-life measures. Fluid retention was the principal reported adverse effect and improved after dose reduction.
Study administration: Protocol-specific recombinant human growth hormone replacement or placebo
Limitations: Findings apply to diagnosed adult GH deficiency under monitored replacement. They do not establish benefit in healthy adults, athletes, or anti-aging use.
Randomized placebo-controlled factorial trial of GH and sex steroids
Healthy older women and men
GH increased lean mass and reduced fat mass, but strength and aerobic benefits were inconsistent. Edema, arthralgias, carpal-tunnel symptoms, diabetes, and glucose intolerance were more frequent in GH-treated groups.
Study administration: Protocol-specific recombinant GH, sex steroids, combinations, or placebo
Limitations: Combined-hormone arms complicate attribution, and frequent adverse effects make the trial unsuitable as support for routine anti-aging use.
Randomized placebo-controlled study with IGF-1-guided dose adjustment
32 men with adult-onset growth hormone deficiency
Replacement increased bone-density measures and lean mass and reduced body fat in men with adult-onset GH deficiency.
Study administration: Physiologic recombinant GH replacement or placebo
Limitations: Small selected deficiency population. The result cannot be generalized to healthy people or converted into bodybuilding or anti-aging expectations.
Randomized double-blind placebo-controlled trial
52 healthy men older than 69 years with low age-adjusted IGF-1
GH increased lean mass and reduced fat mass but did not produce clinically meaningful improvements in strength, endurance, or cognition.
Study administration: Protocol-specific recombinant GH or placebo
Limitations: Healthy-aging body-composition changes did not translate into functional benefit and do not establish an approved anti-aging indication.
Systematic review of randomized controlled trials
Community-dwelling adults with mean age at least 50 years and no disease-specific GH indication
Across 18 study populations, GH produced small average reductions in fat mass and increases in lean mass without meaningful weight change, while edema, arthralgias, carpal-tunnel syndrome, gynecomastia, and glucose abnormalities were more common.
Study administration: Recombinant GH versus no GH or lifestyle-control comparisons
Limitations: Most studies were small and heterogeneous. The review concluded that GH could not be recommended as anti-aging therapy.
Safety snapshot
Current somatropin labels warn about risks including acute critical illness, active malignancy, glucose intolerance or diabetes, intracranial hypertension, fluid retention, hypothyroidism, hypoadrenalism, and pediatric orthopedic complications.
Other human evidenceIndividual contraindications and monitoring requirements differ by patient and product; Relay does not assess personal suitability.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Current somatropin labels warn about risks including acute critical illness, active malignancy, glucose intolerance or diabetes, intracranial hypertension, fluid retention, hypothyroidism, hypoadrenalism, and pediatric orthopedic complications.
Other human evidenceIndividual contraindications and monitoring requirements differ by patient and product; Relay does not assess personal suitability.
Open sourceThe current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-04-30
2026-04-01
2026-02-24
2025-11-25
2025-07-07
2007-01-16 · PMID 17227934 · DOI 10.7326/0003-4819-146-2-200701160-00005
2003-01-01 · PMID 12570912 · DOI 10.1016/s0025-7753(03)73599-4
2002-11-13 · PMID 12425705
1996-12-15 · PMID 8967668
1996-05-01 · PMID 8633830